# Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

Study · id `cardio:ct-nct03799627` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03799627](<https://clinicaltrials.gov/study/NCT03799627>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03799627

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

## Technical summary

Registry record NCT03799627. Randomized; no masking; primary purpose treatment. Start 2019-01-31 (actual); primary completion 2020-06-05 (actual). Results posted on 2022-09-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Started: 2019-01-31 (actual) (ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Primary completion: 2020-06-05 (actual) (ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Completion: 2020-07-15 (actual) (ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Results first posted: 2022-09-29 (ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03799627, source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03799627-2022-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
- Acronym: FO2RWARD-2
- Condition: Anemia
- Condition: Dialysis-dependent Chronic Kidney Disease
- Intervention (Drug): Vadadustat
- Intervention (Drug): Epoetin Alfa
- Intervention (Drug): Vadadustat TIW
- Lead sponsor: Akebia Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Akebia Therapeutics (`cardio:org-akebia-therapeutics`)

## Provenance

Content hash: 2155bf6ff27cad25e8c156f8fcffb946f8d24dfc746eed81b1ebd3623378ca99
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
